Checkpoint Therapeutics, Inc. (CKPT)

Market Cap	77.72M
Revenue (ttm)	68,000
Net Income (ttm)	-52.32M
Shares Out	36.15M
EPS (ttm)	-2.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	252,596
Open	2.040
Previous Close	2.060
Day's Range	2.030 - 2.150
52-Week Range	1.300 - 3.620
Beta	1.13
Analysts	Strong Buy
Price Target	22.60 (+951.16%)
Earnings Date	Aug 12, 2024

About CKPT

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib,...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 26, 2017
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: CKPT

Financial Performance

In 2023, CKPT's revenue was $103,000, a decrease of -46.35% compared to the previous year's $192,000. Losses were -$51.85 million, -17.21% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for CKPT stock is "Strong Buy." The 12-month stock price forecast is $22.6, which is an increase of 951.16% from the latest price.

Price Target

$22.6

(951.16% upside)

Analyst Consensus: Strong Buy